MedTrace Logo

Study Examining PrEP-001 in Healthy Subjects

NCT03220048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2019-11-12

Study results available
· View outcomes & findings →

Summary

Phase 2 study, looking at the prophylactic efficacy, safety and tolerability to a repeated nasal dose of study drug after being infected with Influenza A/Perth/16/2009 (H3N2) virus.

Conditions

  • Influenza A H3N2

Interventions

DRUG

PrEP-001

OTHER

Placebo Comparator

Sponsors & Collaborators

  • Prep Biopharm Limited

    collaborator INDUSTRY

  • Hvivo

    lead INDUSTRY

Principal Investigators

  • John Efthimiou · Sponsor's representative

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-09-16
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03220048 on ClinicalTrials.gov